Efficacy

Polivy (polatuzumab vedotin-piiq) Efficacy in Treating Lymphoma

Polivy (polatuzumab vedotin-piiq) is a targeted cancer medication approved for the treatment of certain types of lymphoma. Specifically, it is indicated for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies. Polivy is an antibody-drug conjugate that combines an anti-CD79b antibody with a chemotherapeutic agent. Its efficacy was demonstrated in clinical trials where it was used in combination with bendamustine and a rituximab product (BR). The combination showed a significant improvement in overall response rates and complete response rates compared to treatment with BR alone.

In a pivotal phase II study, the combination including Polivy significantly extended progression-free survival (PFS) in patients with relapsed or refractory DLBCL. The median PFS for patients treated with the Polivy combination was substantially longer than for those who received only BR. Moreover, an improvement in overall survival (OS) was also observed, although this outcome requires further validation in subsequent studies to confirm the long-term benefit.

Monjuvi (tafasitamab-cxix) Efficacy in Treating Lymphoma

Monjuvi (tafasitamab-cxix) is another novel therapeutic agent approved for the treatment of relapsed or refractory DLBCL. It is indicated for use in combination with lenalidomide for adult patients who are not eligible for autologous stem cell transplant (ASCT). Monjuvi is a monoclonal antibody that targets CD19, a protein expressed on the surface of pre-B and mature B lymphocytes and on many B-cell malignancies. The efficacy of Monjuvi in combination with lenalidomide was evaluated in a multicenter, single-arm, open-label phase II trial. This combination showed a marked improvement in overall response rate and complete response rate compared to historical controls of monotherapy.

The clinical trial data for Monjuvi also indicated an extension in progression-free survival when used in the specified patient population. The median PFS observed in the trial was encouraging, suggesting that Monjuvi, in combination with lenalidomide, provides a beneficial treatment option for patients with few alternatives. Additionally, the duration of response for patients responding to treatment was substantial, with many patients maintaining their response beyond a year.